• 2001 AREDS study: 80mg zinc + antioxidants clinically proven to help reduce the risk of AMD progression and associated vision loss.*1,2

  • 2013 AREDS Extension Study – long-term benefits of original PreserVision AREDS 80mg zinc + antioxidants formula confirmed at 10 years*

  • 2013 AREDS2 Study results lead the NEI to support an updated AREDS formula,with lutein and zeaxanthin replacing beta-carotene 3,4

  • PreserVision AREDS 2 contains the exact levels of all 6 nutrients recommended by the NEI

To view the AREDS2 study results presentation from the 2013 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Click here >>.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.


  1. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta-carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10)1417-1436. 

  2. Chew EY, Clemons TE, Agrón E, et al; Age-Related Eye Disease Study Research Group. Long-term effects of vitamins C and E, ß-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology. 2013;120(8)1604-1611.

  3. Age-related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19)2005-2015.

  4. NIH study provides clarity on supplements for protection against blinding eye disease. National Eye Institute website. Accessed August 16, 2013.

  5. ARVO website. Results from the Age-Related Eye Disease Study 2 (AREDS2) from the National Eye Institute. 2013 ARVO Annual Meeting, May 5-9, 2013. Video available at: Accessed September 6, 2013.